HCP Connect Contributor
Dr. Amit Desai
Dr. Amit Desai contributes endocrinology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.
Recent Drug Updates
25 total
Endocrinology
FDA Accepts Afrezza for Pediatric Diabetes: First Needle-Free Insulin for Ages 4 and Up
FDA accepts Afrezza inhaled insulin for pediatric diabetes: first needle-free option for ages 4 and older, decision expected May 29, 2026.
Endocrinology
Tirzepatide and Semaglutide: New Weight Loss Protocols for Obesity Management
Tirzepatide and semaglutide present new obesity management protocols for 2026, focusing on effective patient selection and weight loss outcomes.
Endocrinology
Inhaled Insulin and CGM Systems: 2026 Pediatric Diabetes Management Options Compared
Explore the 2026 advancements in inhaled insulin and CGM systems for pediatric diabetes management, enhancing patient outcomes.
Endocrinology
FDA Approves Insulin Icodec: Weekly Dosing for Type 2 Diabetes Management
FDA approves insulin icodec for type 2 diabetes: weekly dosing improves patient adherence and glycemic control.
Endocrinology
FDA Submits NDA for CagriSema: 13.7% Weight Loss in REDEFINE Trial
CagriSema shows 13.7% weight loss in REDEFINE trial; FDA NDA submitted for obesity treatment.
Endocrinology
GLP-1 Receptor Agonists 2026: Comprehensive Comparison of Orforglipron, Tirzepatide, and Semaglutide
WHO guidelines update on GLP-1 receptor agonists: orforglipron, tirzepatide, semaglutide for obesity treatment.
Endocrinology
ADA Updates Diabetes Treatment Guidelines: GLP-1 and SGLT2 Prioritized for Cardiovascular and Kidney Outcomes
ADA updates diabetes treatment guidelines emphasizing GLP-1 and SGLT2 inhibitors for improved cardiovascular and kidney outcomes.
Endocrinology
FDA Proposes Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List
FDA proposes exclusion of semaglutide, tirzepatide, and liraglutide from 503B bulks list, affecting clinical practices and patient treatment options.
Endocrinology
FDA Approves Orforglipron for Obesity: Oral GLP-1 Therapy with No Food Restrictions
FDA approves orforglipron for obesity: oral GLP-1 therapy with no food restrictions, improving patient compliance and treatment outcomes.
Endocrinology
Wegovy vs Rybelsus: GLP-1 Efficacy and Dosing Comparison for Obesity Management
Wegovy and Rybelsus: WHO guidelines confirm GLP-1 efficacy for obesity management, highlighting dosing and clinical implications.
Endocrinology
GLP-1 Receptor Agonists Reduce Cardiovascular Events: Key Insights for 2024
GLP-1 receptor agonists reduce cardiovascular events by 28% in patients with obesity and diabetes, emphasizing their role in treatment.
Endocrinology
FDA Approves Zepbound for Weight Management: Key Dosing Differences from Mounjaro
FDA approves Zepbound for chronic weight management, highlighting key dosing differences from Mounjaro for obesity treatment.
Endocrinology
Semaglutide: Key Differences Between Ozempic and Wegovy for Diabetes and Weight Loss
Explore the differences between Ozempic and Wegovy semaglutide for diabetes and weight loss, including dosing and clinical implications.
Endocrinology
Exploring the Expanding Role of GLP-1 Receptor Agonists Beyond Diabetes Management
Discover the expanding roles of GLP-1 receptor agonists in obesity, cardiovascular health, and neuroprotection beyond diabetes management.
Medical Research
Identify 5 Overeating Types for Targeted Interventions
Wearable sensors track eating habits to inform personalized obesity care and tailored interventions for better patient outcomes.
Healthcare Business
Targeted AFib Screening: Improved Outcomes
Learn how targeted atrial fibrillation screening can improve patient outcomes and reduce unnecessary tests in your practice, despite controversy over mass screening.
Healthcare Business
Boost Rural Healthcare with $10B Annual Funding
Discover how to access $50 billion in federal funding to enhance rural healthcare, improve provider recruitment, and adopt innovative technology.
Healthcare Business
Medicare Pay Cuts: 2.5% Reimbursement Reduction Looms
Proposed 2026 Medicare pay changes may cut reimbursement by 2.5% for thousands of procedures, affecting doctor pay and practice expenses.
Medical Research
Cut Diabetic Retinopathy Risk by 30% with GLP-1 Therapy
New research suggests GLP-1 receptor agonist drugs like semaglutide can significantly reduce diabetic retinopathy risk, a common diabetes complication.
Digital Health
Cut Pre-Op Admin Time with Digital Forms
Streamline pre-operative assessments with digital forms, reducing admin burden and enhancing patient engagement through remote access.
Medical Research
Eczema Patients at 30% Higher Risk of Suicidal Thoughts
New study reveals atopic eczema patients face increased risk of suicidal ideation, identifying key factors driving this elevated risk for better patient care.
Medical Research
Stroke Recovery Boosted by 7-Day Neural Progenitor Cell Transplant
Discover how transplanting hiPSC-NPCs 7 days post-stroke leads to long-term graft survival and potential for improved patient outcomes in stroke recovery.
Wellness
Reduce Blood Clot Risk 30% with Simple Desk Habits
Learn how to minimize the risk of deadly blood clots with simple changes to your daily desk routine and recognize the signs of venous thromboembolism.
Pharmaceutical
Vaccine Access Updates: What Physicians Need to Know
Stay informed on potential changes to US immunization policy and vaccine access, and how it may impact your practice and patient care.
Medical Research
New Treatment Cuts Vision Loss in LHON Patients
Discover how a novel treatment for Leber's Hereditary Optic Neuropathy (LHON) can help prevent sudden vision loss in patients, now approved for NHS use.